Severe Nodulocystic Acne — Enlarged Glands, Excess Sebum
Placeholder: severe acne begins with oversized, overactive sebaceous glands.
- 100%: Baseline gland size (placeholder reference value)
- 100%: Sebum output (placeholder baseline rate)
- ~40: Active lesions (placeholder nodules/papules)
- Clogged: Follicle status (placeholder keratin plugging)
Gland hypertrophy and sebum overproduction
Placeholder: androgen-driven glands enlarge and overproduce sebum.
Follicular plugging and inflammation
Placeholder: sebum and keratin clog follicles, triggering inflammation.
Isotretinoin Initiated — Weight-Based Systemic Dosing
Placeholder: oral isotretinoin dosed by body weight begins treatment.
- 0.5 mg/kg/day: Typical starting dose (placeholder dosing regimen)
- 120–150 mg/kg: Target cumulative dose (placeholder full-course goal)
- 4–6 months: Course length (placeholder typical duration)
- Monthly labs: Monitoring (placeholder safety tracking)
Mechanism of action on the gland
Placeholder: isotretinoin reduces sebocyte proliferation and gland size.
Dose accumulation over time
Placeholder: cumulative dose builds gradually across the therapy course.
Sebaceous Glands Shrink Up To 90% Over Weeks To Months
Placeholder: continued therapy dramatically shrinks the sebaceous glands.
- ~90%: Max gland reduction (placeholder histologic finding)
- Weeks: Onset of shrinkage (placeholder early response)
- By month 4–6: Peak effect (placeholder full-course timing)
- Apoptosis: Mechanism (placeholder sebocyte cell death)
Histological shrinkage of the gland
Placeholder: sebocyte apoptosis and reduced differentiation shrink glands.
Dose-response relationship
Placeholder: higher cumulative dose drives deeper, longer-lasting shrinkage.
Sebum Production Falls, Follicles Clear, Lesions Resolve
Placeholder: shrunken glands secrete far less sebum, clearing follicles.
- Up to 90%: Sebum reduction (placeholder secretion drop)
- Markedly reduced: Follicle clogging (placeholder comedone decline)
- Resolving: Inflammatory lesions (placeholder lesion count falls)
- Improving: Skin texture (placeholder visible clearance)
Sebum decline follows gland shrinkage
Placeholder: smaller glands produce proportionally less surface sebum.
Lesion resolution and skin clearing
Placeholder: fewer clogged follicles mean fewer new inflammatory lesions.
Durable Remission After A Complete Treatment Course
Placeholder: a full course often yields long-term, drug-free remission.
- ~60–85%: Remission after 1 course (placeholder long-term response)
- ~15–40%: Relapse needing retreatment (placeholder recurrence rate)
- Only cure: Comparison to topicals (placeholder unique durability)
- 4–6 months: Full course length (placeholder standard duration)
Why remission outlasts treatment
Placeholder: gland suppression persists well beyond stopping the drug.
Comparison with other acne therapies
Placeholder: other treatments work only while continued; this one lasts.
Placeholder: isotretinoin remains the only acne therapy offering long-term remission.